This Monday, May 17, 2021, the Sanofi laboratory published the positive results of its phase two clinical trial on its main candidate vaccine against Covid-19 developed with the British GSK. According to the pharmaceutical group, the vaccine induced the production of high concentrations of neutralizing antibodies in participants in all age groups.
High concentration of neutralizing antibodies
The French laboratory Sanofi published this Monday, May 17, 2021 the positive results of a clinical trial on its main candidate vaccine against Covid-19. This is a phase 2 study conducted in adults aged 18 and over ” in order to assess the tolerance, reactogenicity and immunogenicity of two injections administered 21 days apart “. In a press release, the pharmaceutical group reveals that the vaccine has ” induces the production of high concentrations of neutralizing antibodies in adults of all age groups at levels comparable to those seen in people who have recovered from Covid infection “.
Specifically, the results showed “ seroconversion in 95-100% of cases after administration of a second dose “. Scientists have also observed a strong immune response in people who have already been infected. According to Sanofi, this “ underlines the strong potential interest represented by its development for booster vaccination “.
A vaccine expected in the fourth quarter of 2021
Developed with the British GSK, Sanofi’s Covid-19 vaccine candidate uses the same technology as that of the seasonal flu vaccine. It is therefore a vaccine based on recombinant protein which makes it possible to replicate the genetic code of proteins on the surface of the virus. If the phase 2 trials reveal positive results, these will have to be confirmed during phase 3. Last step before a potential market authorization, the phase 3 study provides for the recruitment of more than 35,000 participants in several countries. .
According to the French pharmaceutical group, the phase 3 trial would begin ” in a few weeks ”And will allow, in addition to confirming the results of phase 2, to test the vaccine candidate against the variants of the coronavirus. Subject to positive results from phase 3, Sanofi indicated that the vaccine “ expected to be approved in Q4 2021 “.
